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ABSTRACT
Day 15 absolute lymphocyte count (ALC-15) after autologous peripheral blood hematopoietic stem cell trans-
plantation (APHSCT) has been reported to be a significant predictor for survival in multiple hematologic malig-
nancies. Limitations of previous reports included their retrospective nature and the lack of ALC-15 lymphocyte
subset analyses. To address these limitations, from February 2002 until February 2007, 50 non-Hodgkin lym-
phoma (NHL) patients were enrolled in a prospective study. The primary endpoint of the study was to confirm
prospectively the ALC-15 survival role after APHSCT in NHL. The secondary endpoint was to identify the
ALC-15 lymphocyte subset affecting survival after APHSCT. With a median follow-up of 22.2 months (range:
6-63.7 months), patients with an ALC-15 $500 cells/mL (n 5 35) experienced superior overall survival (OS)
and progression-free survival (PFS) compared with those who did not; median OS: not reached versus 5.4
months, 3-year OS rates of 80% (95% confidence interval [CI]: 55%-95%) versus 37% (95% CI: 15%-65%),
P\ .0001; and median PFS: not reached versus 3.3 months, 3-year PFS rates of 63% (95%CI: 40%-85%) versus
13% (95%CI: 4%-40%), P\ .0001, respectively. Univariately, CD161/561/CD32 natural killer (NK) cells were
the only ALC-15 lymphocyte subset identified as a predictor for survival. Patients with an NK cell count $80
cells/mL (n 5 38) experienced superior OS and PFS compared with those who did not (median OS: not reached
versus 5 months, 3-year OS rates of 76% [95% CI: 57%-92%] versus 36% [95% CI: 11%-62%], P\ .0001; and
median PFS: not reached versus 3months, 3-year PFS rates of 57% [95%CI: 38%-85%] versus 9% [95%CI: 1%-
41%], P\ .0001, respectively). Multivariate analysis showed that NK cells are an independent predictor for sur-
vival. This is the first study confirming the ALC-15 survival role prospectively and identifyingNK cells as the key
ALC-15 lymphocyte subset affecting survival after APHSCT.
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The clinical efficacy of autologous peripheral
blood hematopoietic stem cell transplantation
(APHSCT) in treatingmalignancies has been solely at-
tributed to the high-dose chemotherapy to eradicate
tumor cells [1]. However, despite high-dose chemo-
therapy, APHSCT is still not curative for a number
of patients with malignant diseases [1]. One hypothesis
for the high relapse rate observed in APHSCT is thepresumptive lack of graft-versus-tumor (GVT) effect
present in allogeneic stem cell transplantation (Allo-
SCT),where it is associatedwith a significant therapeu-
tic impact on clinical outcomes [2]. Recent reports have
shown that early posttransplant lymphocyte recovery
has a direct impact on survival in patients undergoing
Allo-SCT [3,4], suggesting that the early lymphocyte
recovery posttransplant can be used as a surrogate
maker for GVT.807
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absolute lymphocyte count at day 15 (ALC-15) after
APHSCT has been reported as a significant, indepen-
dent prognostic factor for survival in acute myeloge-
nous leukemia (AML) [5], breast cancer [6,7],
Hodgkin lymphoma (HL) [8,9], non-Hodgkin lym-
phoma (NHL) [9-13], multiple myeloma (MM)
[10,13,14], and primary systemic amyloidosis [15],
suggesting the possibility of an autologous GVT sim-
ilar to the GVT seen in the Allo-SCT. Limitations of
these previous publications included their retrospec-
tive nature and the lack of ALC-15 lymphocyte subset
analysis. To address these limitations, we prospec-
tively enrolled NHL patients in a study to determine
the role of ALC-15 on survival and to identify the
ALC-15 lymphocyte subset affecting survival after
APHSCT.
MATERIALS AND METHODS
To participate in the study, patients were required
to be candidates for APHSCT, have chemosensitive
disease prior to APHSCT, mobilize stem cells using
growth factor only (granulocyte-colony stimulating-
factor [G-CSF]), signed informed consent for partici-
pation, and were willing to have research blood col-
lected at day 15 post-APHSCT. Patients were
excluded if they refused to provide consent, failed to
mobilize stem cells by G-CSF and required bone mar-
row harvest, were infused with both peripheral blood
and bone marrow harvest-derived stem cells, or partic-
ipated in clinical trials. No patients were lost to follow-
up. From February 2002 to February 2007, 50 NHL
patients were enrolled in the study. All patients signed
written, informed consent to participate in the study.
Approval of the study was obtained from the Mayo
Clinic institutional review board, and was in accor-
dance with U.S. federal regulations and the Declara-
tion of Helsinki.
Endpoints
The primary endpoint of the study was to assess
prospectively the impact of ALC-15 on overall survival
(OS) and progression-free survival (PFS) from the time
of APHSCT. The second endpoint was to determine
the ALC-15 lymphocyte subset affecting survival after
APHSCT.The third endpointwas to confirmprospec-
tively the role of the autograft absolute lymphocyte
count (A-ALC) with the ALC-15 recovery post-
APHSCT.
A-ALC, ALC-15, and ALC-15 Lymphocyte Subset
Analysis
A-ALC was determined as previously reported: %
collection lymphocytes  absolute autograft white
blood cell count)/kilogram (kg). ALC-15 was deter-
mined from the differential white blood cell count ob-tained at day 15 post-APHSCT [16]. The ALC-15
lymphocyte subset was analyzed as follows: mononu-
clear cells from peripheral blood samples at day 15
post-APHSCT were collected and concentrated to
1  106 cells/mL. According to the manufacture’s
recommendations, immunophenotyping was per-
formed for the T cell panel (CD3/CD4/CD8), B cell
(CD19), and natural killer (NK) cells (CD161/
CD561/CD32). Stained cells were then analyzed us-
ing flow cytometry (FACScallibur, Becton-Dickson,
CA). Cells were analyzed for the percentage of cells
expressing said antigens as well as the average quantity
of antigen expression.
Prognostic Factors
Prognostic factors for post-APHSCTOS and PFS
evaluated in this study included the International
Prognostic Index (IPI) (age $60, extra-nodal sties
$2, lactate dehydrogenase [LDH], performance status
[PS]$2, and stage$3) [17]. In addition, disease status
prior to transplant (complete remission versus partial
response), the infused CD341 cell dose, ALC-15,
A-ALC, and ALC-15 lymphocyte subsets: day 15
CD3 (CD3-15), day 15 CD4 (CD4-15), day 15 CD8
(CD8-15), day 15 CD19 (CD19-15), and day 15
CD161/561/32 ([CD161/561/32]215), and the
number of prior treatments before APHSCT $2
were also evaluated.
Peripheral Blood Stem Cell Collection
All patients received G-CSF (10 mg/kg) daily for
5 to 7 consecutive days by subcutaneous injection.
Once their peripheral blood CD341 cell count was
$10 cells/mL, patients began daily apheresis until
they achieved a target of 5  106 CD341 cells/kg. A
minimum target of 2  106 CD341 cells/kg was re-
quired for the patient to be considered for transplanta-
tion. Patients were assigned to either the Baxter
Amicus (Baxter, Healthcare Corp., Deerfield, IL),
Fenwal CS 3000 Plus (Baxter), or COBE Spectra
(Gambro BCT, Lakewood, CO) based on instrument
availability on the day of collection. Instrument set-
tings used for the collection procedures have previ-
ously been described [18]. The number of apheresis
collections was dependent upon collection of an ade-
quate number of CD341 cells to achieve hematologic
engraftment post-APHSCT.
Conditioning Regimen
All patients receivedCarmustine (BCNU)300mg/m2
on day 26; etoposide 100 mg/m2 twice a day on days
25, 24, 23, and 22; cytarabine 100 mg/m2 twice
a day on days 25, 24, 23, and 22; and melphalan
140 mg/m2 on day 21 (BEAM). All patients received
growth factor support starting on day 16 with sargra-
mostim 500 mg daily until evidence of neutrophilic
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(ANC) $500 cells/mL on 3 consecutive days.
Response and Survival
Response criteria were based on the guidelines
from the NHL international Workshop [19]. Com-
plete response (CR) was defined as complete regres-
sion of all measurable or evaluable disease including
radiologically demonstrable disease, bone marrow in-
volvement, or peripheral blood involvement. Partial
response (PR) was defined as a 50% or greater reduc-
tion in the sum of the products of the longest diameter
and perpendicular diameters of measurable lesion(s),
with a 50% or greater decrease in hepatomegaly or
splenomegaly (measured from the costal margin) in
the presence of previously known liver or spleen in-
volvement. Stable disease was defined as less than PR
with no progressive disease. Disease progression was
defined as a 50% or more increase in the sum of the
products of the longest diameter and the perpendicular
diameter of measurable lesion(s) from the prestudy
measurement, the appearance of new lesions, or
a 2-cm increase in spleen or liver size because of lym-
phoma. Relapsed disease was defined as the appearance
of any new lesion or increase by 50% or more in the
size of previously involved sites.
OS wasmeasured from the date of transplant to the
date of death or last follow-up. PFS was defined as the
time from transplant to the time of progression,
relapse, death, or last follow-up.
Statistical Analysis
OS, PFS, and actuarial risk of relapse were ana-
lyzed using the approach of Kaplan and Meier [20].
Differences between survival curves were tested for
statistical significance using the 2-tailed log-rank
test. The Cox proportional hazards model [21] was
used to evaluate ALC-15 and ALC-15 lymphocyte
subsets as a prognostic factor for post-APHSCT OS
and PFS times as well as to assess and adjust for other
known prognostic factors. Multivariate analysis done
using Cox regression models tested all variables with
a P # .2 in the univariate analysis. CD3-15, CD4-15,
CD8-15, and CD19-15 were used as continuous vari-
ables. Our data did not show any correlation between
a specific cut off point and clinical outcomes for these
variables. A cut off of$80 [CD161/56–/32]215 cells/
mL was supported by the data as it yielded the greatest
differential in survival based on c2 values analyzed at
different cut off points (between the 25th and 75th
quartiles) from log-rank tests.
Prediction of ALC-15 was explored further in lo-
gistic regression models, univariately assessing contin-
uous and dichotomized values of ALC-15 lymphocyte
subsets. c2-tests were used to determine relationships
between categoric variables. The Wilcoxon-rank testwas used to determine associations between continu-
ous variable and categories, and Spearman correlation
coefficients were used to evaluate associations for
continuous variables. All P-values represented were
2-sided and statistical significance was declared at
P\ .05.
RESULTS
Patient Characteristics
The median age at the time of transplant for this
cohort of 50 patients was 57.7 years (range: 23-73).
Distributions of additional baseline characteristics
for these patients are presented in Table 1, and are
summarized based on whether patients achieved an
ALC-15 $500 cells/mL versus \500 cells/mL. The
only differences between the groups were the infused
A-ALC, CD8-15, and [CD161/561/32]215. None
of the patients received purged or CD341 selected
stem cells.
No patients were lost to follow-up. The median
follow-up for the cohort was 22.2 months (range:
6-63.7months). By the time of this analysis, 21 patients
(42%) had evidence of relapse and 12 patients (24%)
had died. The day 100 treatment-related mortality
(TRM) for the cohort was only 2% (1 of 50). One pa-
tient died of an intracranial bleed, the rest because of
progressive lymphoma.
Posttransplant Survival and ALC-15
The median posttransplant OS (Figure 1a) and
PFS (Figure 1b) times were significantly better for pa-
tients who achieved an ALC-15 $500 cells/mL com-
pared with patients with an ALC-15 \500 cells/mL
(not reached versus 5.4 months, 3-year OS rates of
80% (95% CI: 55%-95%) versus 37% (95% CI:
15%-65%), P \ .0001; not reached versus 3.3
months, 3-year PFS rates of 63% (95% CI:
40%-85%) versus 13% (95% CI: 4%-40%), P \
.0001, respectively).
Day 15 Post-APHSCT Lymphocyte Subsets and
ALC-15
By day 15 post-APHSCT, 30% (15 of 50) achieved
normal CD3 count (normal range: 582-1992 cells/mL),
18% (9 of 50) normal CD4 count (normal range: 401-
1532 cells/mL), 38% (19 of 50) normal CD8 count
(normal range: 152-838 cells/mL), 4% (2 of 50) normal
CD19 count (normal range: 71-567 cells/mL), and
76% (38 of 50) normal CD161/561/32 count (natural
killer [NK] cells) (normal range: 80-597 cells/mL). By
univariate analysis, we identified a correlation between
ALC-15 and CD3-15 (rs 5 0.4, P\ .006), CD4-15
(rs 5 0.36, P\ .01), CD8-15 (rs 5 0.41, P\ .004),
and [CD161/561/32]215 (rs 5 0.62, P \ .0001).
No correlation was identified between ALC-15 and
CD19-15 (rs 5 0.04, P 5 .72) or ALC-15 and CD34
810 L. F. Porrata et al.Table 1. Baseline Characteristics of Patients According to ALC-15 ($500 versus\500 cells/mL)
Characteristics ALC-15 $500 Cells/mL (N 5 35) ALC-15\500 Cells/mL (N 5 15) P-Value
Age, years, median (range) 56 (23-71) 60 (46-73) .18
Sex .53
Female 13 4
Male 22 11
Lymphoma type .35
DLBCL 23 11
Mantle cell 8 2
T cell 4 1
Follicular 0 1
Prognostic factors at diagnosis
Extra nodal sites .41
0 21 11
1 11 4
2 2 0
LDH (U/L), median (range) 200 (150-1515) 225 (152-358) .47
Performance status .47
0 21 10
1 12 5
2 2 0
Stage .45
I 5 1
II 2 3
III 6 2
IV 22 9
IPI factors
Age, years .55
$60 15 8
\60 20 7
LDH .36
Abnormal 13 8
Normal 22 7
Extra nodal sites .22
$2 2 0
\2 33 15
Performance status .23
$2 2 0
\2 33 15
Stage .71
I/II 7 4
III/IV 28 11
IPI score .4
0 4 1
1 11 4
2 15 7
3 5 3
IPI index .75
$2 20 10
\2 15 5
Apheresis machine .28
Baxter Amicus 23 9
Fenwal CS 3000 2 3
COBE Spectra 10 3
Number of prior treatments before APHSCT .14
1 9 1
2 24 11
3 2 2
4 0 1
Disease status prior to salvage chemotherapy .09
CR 7 0
Relapse 28 15
Disease status prior to APHSCT .18
CR 13 2
PR 22 13
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Characteristics ALC-15 $500 Cells/mL (N 5 35) ALC-15\500 Cells/mL (N 5 15) P-Value
Number of apheresis collection, median (range) 4 (1-7) 3 (2-7) .29
Infused CD341 cells  106/kg, median (range) 4.76 (2.03-8.56) 3.93 (2.26-8.03) .81
Infused A-ALC lymphocytes  109/kg, median (range) 0.609 (0.187-1.655) 0.183 (0.02-1.263) \.003
CD3-15 cells/mL, median (range) 421 (8-2069) 165 (0.3-1413) .09
CD4-15 cells/mL, median (range) 171.5 (3-1091) 123 (19.7-793) .27
CD8-15 cells/mL, median (range) 151.5 (3-813) 63 (13-570) \.02
CD19-15 cells/mL, median (range) 2 (0-227) 1 (0-10) .58
[CD161/561/32]215 cells/mL, median (range) 134 (66-999) 91 (10-231) \.0001
A-ALC indicates autograft, absolute lymphocyte count; APHSCT, autologous hematopoietic stem cell transplantation; CR, complete remission;
DLBCL, diffuse large B cell lymphoma; IPI, International Prognostic index; LDH, lactate dehydrogenase; PR, partial response.(rs5 0.11, P5 .5). When CD3-15, CD4-15, CD8-15,
and [CD161/561/32]215 were accounted for in
a multivariate logistic regression model, [CD161/
561/32]215 was the only remaining significant corre-
late for ALC-15 (P\ .0001).
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Figure 1. (a) OS of patients with an ALC-15 $500 cells/mL versus
patients with an ALC-15\500 cells/mL. The median OS was not
reached in the group of patients with an ALC-15 $500 cells/mL
and in 5.4 months with the group of patients with an ALC-15
\500 cells/mL. The OS rates at 3 years were 80% and 37%, respec-
tively (P\ .0001). (b) PFS of patients with an ALC-15$500 cells/mL
versus patients with an ALC-15\500 cells/mL. Themedian PFSwas
not reached in the group of patients with an ALC-15$500 cells/mL
and in 3.3 months with the group of patients with an ALC-15\500
cells/mL. The PFS rates at 3 years were 63% and 13%, respectively
(P\ .0001).ALC-15 Lymphocyte Subset and Relapse
Twenty-one patients relapsed at a median of 5.1
months (range: 1.2-28.4 months) with a 3-year actuar-
ial risk of relapse for NK cells of 21% (95% CI: 12%-
45%); CD3-15 of 45% (95% CI: 30%-70%); CD8-15
of 48% (95% CI: 35%-75%); CD4-15 of 54% (95%
CI: 32%-73%); and CD19-15 of 60% (95% CI:
30%-80%) (Figure 2).
Posttransplant Survival and NK Cells
NK-15[CD161/561/32]215,asacontinuousvari-
able, was the only ALC-15 lymphocyte subset associ-
ated with OS and PFS after APHSCT (Table 2). The
median posttransplant OS (Figure 3a) and PFS
(Figure 3b) times were significantly better for patients
who achieved an NK cell at day 15 (NK-15)$80 cells/
mL compared with patients with an NK-15\80 cells/
mL (not reached versus 4.9 months, 3-year OS rates of
76% [95% CI: 57%-92%] versus 36 [95% CI:
11%-62%], P\ .0001; not reached versus 3.0 months,
3-year PFS rates of 57% [95% CI: 38%-85%] versus
9% [95% CI: 1%-41%], P \ .0001, respectively).
Patients with an ALC-15\500 cells/mL (N5 15), but
withanNK-15$80cells/mL(N54), experiencedsupe-
rior OS and PFS post-APHSCT compared with those
who did not (not reached versus 4.6 months, 3-year
OS rates of 67% [95% CI: 35%-95%] versus 27%
[95% CI: 9%-55%], P\ .04; 17 versus 2.8 months,
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Figure 2. Actuarial risk of relapse for ALC-15 lymphocyte subsets.
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Overall Survival Progression-Free Survival
Prognostic Factors RR 95%CI P-Value RR 95%CI P-Value
Age $60 years 1.042 0.985-1.116 .16 1.046 1.000-1.101 .06
ALC-15 $500 cells/mL 0.342 0.161-0.626 \.0004 0.403 0.253-0.623 \.0001
A-ALC 0.262 0.030-0.629 \.01 0.165 0.017-0.518 \.004
Extra nodal sites .1 1.520 0.352-3.561 .46 1.094 0.257-2.436 .87
LDH abnormal 1.342 0.757-2.470 .31 0.998 0.997-1.011 .20
PS .1 1.231 0.681-1.386 .24 1.125 0.512-4.771 .81
Stage III/IV 1.757 0.774-7.513 .20 1.371 0.797-2.832 .28
Disease status at transplant: CR 0.495 0.116-1.129 .11 0.627 0.303-1.080 .10
Infused CD34 (continuous variable) 1.174 0.855-1.600 .30 1.033 0.798-1.311 .80
Apheresis machine S versus A/F 0.274 0.181-1.017 .06 0.247 0.161-0.967 \.05
CD3-15 1.000 0.499-1.001 .67 0.999 0.998-1.000 .71
CD4-15 1.000 0.998-1.002 .68 0.999 0.997-1.001 .81
CD8-15 1.000 0.997-1.003 .81 0.999 0.996-1.002 .58
CD19-15 0.991 0.926-1.008 .49 0.984 0.919-1.003 .17
[CD161/56–/32]215 0.671 0.531-0.831 \.01 0.796 0.682-0.917 \.03
[CD16–/561/32]215 $80 cells/mL 0.328 0.169-0.587 \.0002 0.382 0.245-0.592 \.0001
Number of prior treatments before APHSCT $2 1.878 0.532-2.171 .4 0.934 0.319-1.699 .9
A indicates Amicus machine; ALC, absolute lymphocyte count; A-ALC, autograft, absolute lymphocyte count; F, Fenwal CS 3000 machine;
LDH, lactate dehydrogenase; PS, performance status; S, Spectra machine; RR, relative risk, CI, confidence interval.3-yearPFSratesof25%[95%CI:10%-70%]versus9%
[95%CI: 1%-40%], P\ .05, respectively).
NK-15, Disease Status, and Prior Treatment to
APHSCT
NK-15 was able to discriminate among patients
who were heavy ($2 prior treatments) or less (1 treat-
ment) pretreated and patients who presented in CR or
PR prior to APHSCT. In the less pretreated group (N
5 10), the median posttransplant OS and PFS (times
were significantly better for patients who achieved an
NK cell at day 15 [NK-15]$80 cells/mL [N5 7] com-
pared with patients with an NK-15\80 cells/mL [N
53]) (not reached versus 5 months, 3-year OS rates
67% [95% CI: 23%-91%] versus 0%, P\ .0001; not
reached versus 2.6 months, 3-year PFS rates of 65%
[95% CI: 27%-92%] versus 0%, P \ .003, respec-
tively). In the heavy pretreated group (N 5 40), the
median posttransplant OS and PFS times were signif-
icantly better for patients who achieved an NK cell at
day 15 (NK-15) $80 cells/mL (N 5 32) compared
with patients with an NK-15\80 cells/mL (N 5 8)
(not reached versus 3 months, 3-year OS rates of
85% [95% CI: 58%-98%] versus 36% [95% CI:
18%-65%], P\ .003; not reached versus 3.0 months,
3-year PFS rates of 63% [95% CI: 40%-87%] versus
9% [95% CI: 1%-43%], P\ .0001, respectively). In
the CR group (N5 15) prior to APHSCT, the median
posttransplant OS and PFS times were significantly
better for patients who achieved an NK cell at day 15
(NK-15) $80 cells/mL (N 5 13) compared with pa-
tients with an NK-15 \80 cells/mL (N 5 2) (not
reached versus 10 months, 3-year OS rates of 100%
versus 50% [95%CI: 20%-80%], P\ .01; not reachedversus 3.0 months, 3-year PFS rates of 90% [95% CI:
60%-100%) versus 0%, P \ .0001, respectively). In
the PR group (N 5 35), the median posttransplant
OS and PFS times were significantly better for patients
who achieved an NK cell at day 15 (NK-15)$80 cells/
mL (N 5 25) compared with patients with an NK-15
\80 cells/mL (N 5 10) (not reached versus 5 months,
3-year OS rates of 72% [95% CI: 48%-93%] versus
30% [95% CI: 10%-61%], P \ .0005; not reached
versus 3.3 months, 3-year PFS rates of 52% [95%
CI: 30%-77%] versus 10% [95% CI: 1%-43%], P\
.0004, respectively).
Source of ALC-15 and ALC-15 Lymphocyte
Subsets
To confirm prospectively our previous retrospec-
tive reports demonstrating that A-ALC correlated
with ALC-15, we analyzed if A-ALC or infused
CD341 cells not only correlated with ALC-15, but
also with ALC-15 lymphocyte subsets. First we identi-
fied no association between the collected CD341 cells
and A-ALC (rs 5 0.001, P 5 .95). There was no
association between CD341 cells and ALC-15 (rs 5
.11, P 5 .5), CD3-15 (rs 5 0.16, P 5 .3), CD4-15 (rs
5 .16, P 5 .3), CD8-15 (rs 5 .21, P 5 .1), CD19-15
(rs 5 .04, P 5 .8), and [CD16
1/561/32]215 (rs 5
.11, P 5 .4). On the contrary, we identified an associ-
ation between A-ALC and ALC-15 (rs 5 .55, P \
.0001), CD3-15 (rs 5 .29, P\ 0.04), CD4-15 (rs 5
0.28, P \ .05), CD8-15 (rs 5 .32, P \ .02), and
[CD161/561/32]215 (rs5 .38, P\ .007). No associ-
ation was observed between A-ALC and CD19-15
(rs 5 .14, P 5 .32). Patients who achieved an ALC-
15 $500 cells/mL were infused with a higher A-ALC
Lymphocytre Recovery and Survival 813versus those who achieved an ALC-15\500 cells/mL
(0.609 [range: 0.187-1.655] versus 0.183 [range: 0.02-
1.263] 109 lymphocytes/kg, P\.0027, respectively).
Despite setting the specific apheresis instrument pa-
rameters to collect CD341 cells, the COBE Spectra
collected more A-ALC per collection compared with
the Baxter Amicus and the Fenwal CS3000 Plus
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Figure 3. (a) OS of patients with an NK-15$80 cells/mL versus pa-
tients with anNK-15\80 cells/mL. ThemedianOSwas not reached
in the group of patients with an NK-15 $80 cells/mL and 5 months
with the group of patients with an NK-15\500 cells/mL. The OS
rates at 3 years were 76% and 36%, respectively (P\ .0001). (b)
PFS of patients with an NK-15 $80 cells/mL versus patients with
an NK-15\80 cells/mL. The median PFS was not reached in the
group of patients with an NK-15 $80 cells/mL and 3 months with
the group of patients with an NK-15\500 cells/mL. The OS rates
at 3 years were 57% and 9%, respectively (P\ .0001).(median A-ALC lymphocytes  109/kg: 0.2 [range:
0.034-0.793] versus 0.146 [range: 0.01-0.88] versus
0.105 [range: 0.043-0.265], P\ .04, respectively).
Univariate and Multivariate Analysis
Age, A-ALC, ALC-15, [CD161/561/32]215, dis-
ease status at transplant, apheresis machine, and stage
were predictor for OS; and age, A-ALC, ALC-15,
[CD161/561/32]215, disease status at transplant,
LDH, and apheresis machine were predictor for PFS
as each of these variables reached a P # .2 in the uni-
variate analysis (Table 2). In the multivariate analysis,
[CD161/561/32]215 remained an independent pre-
dictor for OS and PFS post-APHSCT and truncated
ALC-15 and A-ALC (Table 3).
DISCUSSION
Patients achieving an ALC-15$500 cells/mL after
APHSCT have a superior clinical outcome compared
with those who do not [5-15].Major limitations of pre-
vious reports included their retrospective nature and
no ALC-15 lymphocyte subsets analyses to identify
the key ALC-15 lymphocyte subset conveying the su-
perior survival observed with a higher ALC-15 recov-
ery. Therefore, we set out to address these limitations
in a prospective fashion by analyzing not only ALC-15,
but also ALC-15 lymphocyte subsets in NHL patients
undergoing APHSCT.
The stratification of our cohort group using ALC-
15 $500 cells/mL was based on previous publications
[5,6,8,10,15]. Both groups were balanced for all patient
characteristics and prognostic factors except for
A-ALC, CD8-15, and NK cells at day 15 defined as
[CD161/561/32]215. Our study confirmed prospec-
tively that patients achieving an ALC-15 $500 cells/
mL experienced superior survival compared with those
who did not. No association between the ALC-15 and
B cells was identified. A possible explanation for this
observation is the fact that all patients in the study
received prior rituximab therapy depleting the B cell
compartment. However, T cells and NK cells wereTable 3. Multivariate Analysis for Overall and Progression-Free Survival
Overall Survival Progression-Free Survival
Prognostic Factors RR 95%CI P-Value RR 95%CI P-Value
Age $60 years 1.098 1.012-1.204 \.02 1.124 1.050-1.215 \.0004
ALC-15 $500 cells/mL 0.266 0.117-1.143 .8 0.471 0.254-1.743 .15
A-ALC 0.326 0.139-1.358 .8 0.320 0.156-1.477 .15
[CD161/561/32]215 $80 cells/mL 0.521 0.212-0.774 \.0002 0.420 0.241-0.617 \.0001
Disease status at transplant: CR 0.676 0.357-0.855 \.04 0.576 0.481-0.927 \.03
LDH 1.000 0.966-1.003 .63
Apheresis machine S versus A/F 0.366 0.204-1.731 .6 0.504 0.313-1.111 .12
Stage III/IV 1.521 0.852-2.113 .15
A indicates Amicus machine; ALC, absolute lymphocyte count; A-ALC, autograft absolute lymphocyte count; F, Fenwal CS 3000 machine;
LDH, lactate dehydrogenase; PS, performance status; S, Spectra machine; RR, relative risk, CI, confidence interval.
814 L. F. Porrata et al.associated with ALC-15 recovery. By multivariate
analysis, NK cells were the major lymphocyte subset
contributing the ALC-15 recovery. This finding is in
accordance with previous publications regarding im-
mune-reconstitution after transplant, where NK cells
recovered early postallogeneic or autologous stem
cell transplantation [22-25]. NK cells recovered not
only quantitatively, but also qualitatively when com-
pared with the other lymphoid compartments (ie, T
or B cells) at day 15 after APHSCT) [26]. The only
ALC-15 lymphocyte subset associated with clinical
outcome was NK cells. NK-15 was associated with
a lower actuarial risk of relapse compared with the
other ALC-15 lymphocyte subsets. NK cells as a con-
tinuous or dichotomized variable was associated with
post-APHSCT OS and PFS. Moreover, NK-15 was
an independent prognostic factor in the multivariate
analysis compared to A-ALC and ALC-15, suggesting
thatNK-15 is a more specific marker of the autologous
GVT observed in APSHCT.
Identification of ways to enhance ALC-15 and NK
cells-15 recovery will provide new immunologic ther-
apeutic interventions to improve clinical outcomes
post-APHSCT.We previously demonstrated no asso-
ciation between infused CD341 cells and ALC-15, and
this finding is confirmed by the current study. In prior
reports we showed that the infused A-ALC had a direct
impact on ALC-15 recovery in NHL [27] and multiple
myeloma (MM) [28] patients post-APHSCT. Our
findings regarding the association between A-ALC
and ALC-15 have been recently confirmed retrospec-
tively in multiple myeloma (MM) [29,30]. Our study
shows a strong positive correlation not only between
infused A-ALC and ALC-15, but also between A-
ALC and T and NK cells, but not B cells. This obser-
vation is important because stem cell mobilization and
collection in APHSCT should not be viewed only as
a means to achieve hematopoietic engraftment, but
also as a means to achieve immunologic engraftment
with direct consequences to clinical outcome [31].
Because of the strong correlation between A-ALC
and ALC-15 and the fact that A-ALC is known pre-
APSHCT, a low A-ALC pre-APSHCT may translate
into slow ALC-15 recovery, leading to poor clinical
outcomes. To overcome the lack of a immune response
because of a low A-ALC, clinicians may intensify con-
ditioning hoping to improve clinical outcomes post-
APSHCT. Thus, therapeutic maneuvers to enhance
A-ALC collection should translate into better clinical
outcomes after APHSCT. This is confirmed by the
fact that patients who achieved an ALC-15 $500
cells/mL were infused with higher numbers of
A-ALC. To enhance A-ALC collection, we previously
published that the apheresis instruments can affect
A-ALC collection [18]. This is confirmed in this study,
as the settings used at our institution with the COBE
Spectra collected more A-ALC than the settings usedat our institution with the Amicus or the Fenwal
CS3000 Plus, even though the parameters for each
apheresis machine were set to maximize CD341 cell
collection. However, even though the COBE Spectra
collected more A-ALC and was associated with better
survival, in the multivariate analysis, the apheresis ma-
chine statistical significance was canceled out by the
NK-15, suggesting that it is not the apheresis machine
affecting survival; instead, it is the amount of A-ALC
collected by the apheresis machine translating into
a higher ALC-15/NK-15 recovery affecting survival
post-APHSCT. Because of this finding, we have an
opened Phase III randomized double-blind trial to as-
sess if modified apheresis instrument settings com-
pared with the standard settings can improve survival
through higher A-ALC collection translating into
faster immune recovery post-APHSCT.
A limitation of the study is the heterogenous group
of NHL histologies included in the study. However,
ALC-15 has been reported to be an independent prog-
nostic factor for survival in T and B cell NHL, as well
as mantle cell lymphoma post-APHSCT [9-13].
Another limitation of the study is that even though we
identified prospectively an association between ALC-
15 and NK-15 subsets and survival post-APHSCT, it
does not imply causation. We hope that our Phase III
study will directly answer that the alleged survival ad-
vantage observed with early lymphocyte recovery post-
APHSCT is caused by the ALC-15 and theNK-15 sub-
sets. In addition, ALC-15/NK-15 might be a possible
surrogate marker found in less heavily pretreated pa-
tients, which would have better clinical outcomes for
this reason rather than higher lymphocyte count recov-
ery. Nevertheless, we identified that patients with
ahigherNK-15 experienced superior survival regardless
if they were heavy pretreated or not, or if there were in
CR or PR prior to APHSCT.However, larger prospec-
tive studies are warranted to confirm our findings with
a more balance cohort of patients, as younger patients,
higher CR rates pre-APHSCT, and a higher number
of patients with mantle cell lymphoma who would
require longer follow-up to assess progression of disease
were observed in the ALC-15$500 cells/mL group. To
our knowledge, 1 negative study has been published
showing no association between ALC-15 and survival
post-APHSCT in NHL by Tiwari et al. [32]. An expla-
nation for the negative result reported by Tiwari et al.
could be answered by the current study, as themain lim-
itation of the Tiwari et al. study was the lack of ALC-15
lymphocyte subset analysis. In the current study, even
patients with an ALC-15\500 cells/mL, but with an
NK-15 $80 cells/mL, experienced superior survival
comparedwith thosewhodidnot, andNK-15was an in-
dependent prognostic factor compared to ALC-15 in
the multivariate analysis. This finding suggests that
NK-15 could be a more powerful, discriminatory prog-
nostic factor for survival than ALC-15 post-APHSCT.
Lymphocytre Recovery and Survival 815In summary, this is the first study confirming
prospectively the prognostic significance of ALC-15
and identifying NK cells as the key ALC-15 lympho-
cyte subsets conveying the superior survival after
APHSCT. In addition, this study also confirms pro-
spectively that A-ALC is the main source of ALC-15
and ALC-15 lymphocytes subsets. We eagerly await
the results of an ongoing Phase III to enhance A-
ALC collection to maximize ALC-15 recovery with
the hope of improving clinical outcomes post-
APHSCT. Further studies to understand the underly-
ing mechanism of how NK cells eradicate tumor cells
post-APHSCT are warranted [33].
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